ASAIO Journal最新文献

Donation after circulatory death (DCD) livers face increased risks of critical complications when preserved with static cold storage (SCS). Although machine perfusion (MP) may mitigate these risks, its cost and logistical complexity limit widespread application. We developed the Dynamic Organ Storage System (DOSS), which delivers oxygenated perfusate at 10°C with minimal electrical power requirement and allows real-time effluent sampling in a portable cooler. In a porcine DCD model, livers were preserved using DOSS or SCS for 10 hours and evaluated with 4 hours of normothermic MP, with n = 5 per group. After 4 hours of normothermic MP, the DOSS group demonstrated significantly lower perfusate lactate (p = 0.023), increased perfusate fibrinogen (p = 0.005), higher oxygen consumption (p = 0.018), greater bile production (p = 0.013), higher bile bicarbonate levels (p = 0.035) and bile/perfusate sodium ratio (p = 0.002), and lower hepatic arterial resistance after phenylephrine administration (p = 0.018). Histological analysis showed lower apoptotic markers in DOSS-preserved livers, with fewer cleaved caspase-3 (p = 0.039) and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL; p = 0.009) positive cells. These findings suggest that DOSS can enhance DCD allograft function during transport, offering potential clinical benefits and contributing to the expansion of the donor pool.

This 5 year retrospective study presents the clinical experience with preprimed extracorporeal membrane oxygenation (ECMO) circuits used in a Single Hub Center Hospital, focusing on sterility, functionality, and safety. The ECMO program has been active since 2019, with a total of 223 circuits managed. Our preassembled and preprimed ECMO circuits were stored in a sterile environment and continuously circulated until implantation. Sterility and functionality testing was performed at the end of circuit preparation, every 7 days, and before implantation. Our results show that only 2 (0.3%) of the 570 samples tested positive for bacteria, and all implanted devices demonstrated satisfactory gas transfer performance. None of the ECMO devices demonstrated any loss of early functionality after implantation. The longest storage period of a preprimed circuit was 73 days, with no positive culture results. Our study highlights the importance of preassembled and preprimed ECMO circuits in improving clinical practice in emergency situations, highlighting their safety and potential to improve clinical practice. Furthermore, our findings suggest that standardizing guidelines for prepriming and storage of ECMO circuits can help minimize the risk of contamination.

Venoarterial extracorporeal membrane oxygenation (VA-ECMO) benefits patients with cardiogenic shock (CS) but can increase left ventricular afterload and exacerbate pulmonary edema. Adding a percutaneous left ventricular assist device (LVAD) to VA-ECMO can optimize the hemodynamics. Because managing VA-ECMO and LVAD simultaneously is complex and labor-intensive, we developed a closed-loop automated control system for VA-ECMO and LVAD. Based on the circulatory equilibrium framework, this system automatically adjusts VA-ECMO and LVAD flows and cardiovascular drug and fluid dosages to achieve target arterial pressure (AP, 70 mm Hg), left atrial pressure (PLA, 14 mm Hg), and total systemic flow (Ftotal, 120-140 ml/min/kg). In seven anesthetized dogs with CS, VA-ECMO significantly increased AP and PLA from 24 (23-27) to 71 (63-77) mm Hg and 20.1 (16.3-22.1) to 43.0 (25.7-51.4) mm Hg, respectively. Upon system activation, PLA was promptly reduced. At 60 min postactivation, the system-controlled AP to 69 (65-74) mm Hg, PLA to 12.5 (12.0-13.4) mm Hg, and Ftotal to 117 (114-132) ml/min/kg while adjusting VA-ECMO flow to 59 (12-60) ml/min/kg, LVAD flow to 68 (54-78) ml/min/kg, and cardiovascular drug and fluid dosages. This system automatically optimizes VA-ECMO and LVAD hemodynamics, making it an attractive tool for rescuing patients with CS.

We performed a retrospective review comparing outcomes between traditional ice storage (ICE) with short ischemic times (<3 hours) to SherpaPak Cardiac Transport System (SCTS) with long ischemic times (>4 hours) using data from the GUARDIAN registry, a retrospective observational trial. To minimize baseline differences, propensity-matched (PSM) cohorts for site and era were performed. SherpaPak Cardiac Transport System travel distance was almost 10-fold greater than ICE (82 miles ICE vs. 765 miles SCTS). There was no significant difference in primary graft dysfunction (PGD) (20.8% vs. 18.2%, p = 0.58), length of stay (LOS) (24.7 vs. 24.8, p = 0.98), posttransplant mechanical circulatory support (MCS) (25.1% vs. 20.3%, p = 0.34), and 30 day survival (100% vs. 98.6%, p = 0.20). SherpaPak Cardiac Transport System showed statistically significant reduction in 24 hour inotrope scores (17.6 vs. 13.6, p = 0.007) and right ventricular (RV) dysfunction (31.1% vs. 15.7%, p = 0.002). Propensity-matched cohorts showed statistically similar rates of MCS utilization and PGD, but SCTS trended toward less RV dysfunction (26.0% vs. 16.2%, p = 0.11) and lower inotrope scores (16.5 vs. 12.9, p = 0.06) despite almost double the ischemic time. In conclusion, donor heart preservation with SCTS continues to be effective in prolonged ischemic times without sacrificing postheart transplantation clinical outcomes. This may aid in expanding donor organ geography.

The United Network for Organ Sharing (UNOS) 2018 heart allocation policy prioritizes patients receiving temporary mechanical circulatory support (tMCS) given the high waitlist mortality rate of this group. This study evaluates national trends and waitlist outcomes for patients receiving tMCS under the UNOS 2018 allocation policy. Adult patients waitlisted for isolated heart transplantation were included using the UNOS database. The prevalence of tMCS, 90 day waitlist mortality, 90 day incidence of transplantation, and posttransplant 1 year mortality were analyzed. A total of 27,343 patients were waitlisted during the study period (pre-policy change: 13,004 vs. post-policy change: 14,339). The prevalence of tMCS increased from 7.4% (n: 956) to 22.4% (n: 3,186) after the policy change (p < 0.001). The use of Impella increased proportionally among tMCS modalities. Patients on tMCS had lower adjusted odds of waitlist mortality (p < 0.001), higher adjusted incidence of transplantation (p < 0.001), and similar posttransplant mortality (p = 0.10) under the 2018 policy. Patients on extracorporeal membrane oxygenation (ECMO) support had the highest odds of 90 day waitlist mortality (p < 0.05) but also the highest incidence of transplantation in the post-policy change cohort (p < 0.05). In conclusion, the use of tMCS as bridge to heart transplantation increased threefolds and is associated with lower waitlist mortality and higher incidence of transplantation following the UNOS 2018 allocation policy change.

Type II heparin-induced thrombocytopenia and thrombosis (type II HITT) is a rare but serious complication in patients receiving heparin for anticoagulation. In type II HITT, an immune-mediated reaction against platelet factor four-heparin complexes results in thrombocytopenia and an elevated risk of thrombosis. This poses significant challenges for patients with advanced heart failure requiring urgent left-ventricular assist device (LVAD) implantation. The use of direct thrombin inhibitors, the typical alternative to heparin, is associated with increased bleeding risk and lacks a reversal agent, limiting their use in cardiac surgery. We present two cases of intraoperative epoprostenol to facilitate implantation of a durable LVAD in type II HITT, of which one case underwent preoperative plasmapheresis and intravenous immunoglobulin (IVIG) therapy. Epoprostenol, a prostacyclin analog, was used intraoperatively during LVAD implantation to inhibit platelet activation and allowed for the safe administration of heparin during cardiopulmonary bypass. Both patients underwent successful LVAD implantation without thrombotic or major bleeding complications. These cases highlight the potential of using intraoperative epoprostenol in conjunction with preoperative plasma exchange (PLEX) and IVIG to mitigate the risks associated with heparin use in patients with type II HITT, offering an alternative approach for this high-risk group requiring urgent cardiac surgery.